Measurement of antibodies to interferon beta in patients with multiple sclerosis

Archives of Neurology

Volumn 58, Issue 8, 2001, Pages 1299-1300

  Pachner, A R ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA1A INTERFERON; CELL PROTEIN; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEOPTERIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN BINDING; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034888401     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.8.1299     Document Type: Short Survey

References (14)

1. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration: Danish multiple sclerosis study group
2. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS
3. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b
4. Neutralising and binding anti-interferon-beta-1b antibodies during IFN-beta-1b treatment of multiple sclerosis
5. A novel bioassay for the determination of neutralizing antibodies to IFN-beta 1b
6. Anti-cytokine antibodies in beta interferon-treated MS patients and need for testing: The plight of the practicing neurologist
7. Bioavailability of interferon beta-1b in MS patients with and without neutralizing antibodies
8. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis: Multiple Sclerosis Collaborative Research Group (MSCRG)
9. Analysis of antigenic domains on natural and recombinant human IFN-β by the inhibition of biologic activities with monoclonal antibodies
10. Immunological response to repeated administration of recombinant human erythropoietin in rats: Biphasic effect on its pharmacokinetics
11. Incidence and in vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA
12. Guidelines for physicians with patients on IFNβ-1b: The use of an assay for neutralizing antibodies (NABs)
13. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b
14. Antibodies to IFN-beta in multiple sclerosis patients: Measurement by a commercially available kit